 Eli Lilly  Co said an experimental onceweekly drug for Type  diabetes was comparable to Novo Nordisk ASs oncedaily Victoza in reducing a measure of blood sugar in a patient study a finding Lilly hopes will give it a competitive advantage if its drug reaches the market Lilly said its longacting drug dulaglutide wasnt superior to Victoza which had  sales of about  billion Lilly disclosed an abbreviated summary of the trials results in a press release Tuesday and plans to present full data at a scientific
  